Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer communications"
DOI: 10.1002/cac2.12214
Abstract: BACKGROUND Current treatment options for human epidermal growth factor receptor 2 (HER2)-overexpressing gastric cancer at third-line have shown limited clinical benefit. Further, there is no specific treatment for HER2 immunohistochemistry (IHC) 2+ and fluorescence in-situ… read more here.
Keywords: patients her2; her2 overexpressing; junction cancer; gastroesophageal junction ... See more keywords
Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
Sign Up to like & getrecommendations! Published in 2023 at "Open Life Sciences"
DOI: 10.1515/biol-2022-0535
Abstract: Abstract Most patients with metastatic breast cancer or gastric cancer who are treated with trastuzumab, an anti-HER2 monoclonal antibody, become refractory to the drug within a year after the initiation of treatment. Although the combination… read more here.
Keywords: her2 overexpressing; breast; combination; gastric cancers ... See more keywords